CVN424 is a non-dopamine therapy that inhibits G protein-coupled receptor 6 (GPR6), which is an orphan receptor as it has no naturally produced agonist that activates the receptor. The GPR6 inhibition can potentially improve motor and non-motor manifestations of Parkinson’s. The drug was discovered using Cerevance’s NETSseq (Nuclear Enriched Transcript Sort sequencing) platform.
Phase III trial for Cerevance’s lead CNS ... - Cure Parkinson's
Phase III trial for Cerevance’s lead CNS therapy, CVN424, in patients with Parkinson’s disease.
Written by
Farooqji
To view profiles and participate in discussions please or .
1 Reply
•
At this point in time, the Phase 2 trial for CVN424 (N=62) is still in progress, and still recruiting PwPs. It is scheduled to be completed in Feb 2025.
classic.clinicaltrials.gov/...
The purpose of the press release is to report that funding has been secured for a future Phase 3 trial.
Not what you're looking for?
You may also like...
Dr. Tom Foltynie of Cure Parkinson’s Addresses Bydureon (Exanatide) Phase III Trial.
2019 and contemplates starting the two year Phase III trial in October of 2019, but the video says...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
point of unblinding the data for the PD Phase III study, we discovered an unexpected issue: too...
First Patient Dosed in Phase 3 Trial of Buntanetap for Early Parkinson's
placebo-controlled Phase 2a clinical trial (NCT04524351) that included patients with Parkinson’s...
Photopharmics kickstarts phototherapy trial for Parkinson’s disease
The six-month trial will assess the non-invasive device in 300 patients with Parkinson’s, which can...
Electroconvulsive Therapy Intervention for Parkinson’s Disease
before: Electroconvulsive Therapy Intervention for Parkinson’s Disease...
SAFFRON and CNS diseases (PD, AD, etc.)
